Platelet PD-L1 acquired from tumor cells correlates with suppression of CD4+ and CD8+ T-cell function, and a computational model measuring platelet PD-L1 load outperforms traditional histological PD-L1 scoring in predicting ICI responsiveness in NSCLC [55]. The gene discussed is CD4; the disease is neoplasm.